GlassScriptPhysician profile
Fabian Hernandez
NPI 1407440712
$5,481.96
in general payments reported to CMS, 2019-2025
49 companies · $898 in 2025
The $898 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,273 · 2022: $1,472 · 2023: $891 · 2024: $948 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.66 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.69 | 2021-2025 | |
| Amgen INC. | $653.05 | 2021-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $505.33 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $357.44 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $342.16 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $327.08 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $270.15 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.88 | 2021-2024 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $177.77 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $163.13 | 2022-2023 | Austedo, Austedo Xr |
| Esperion Therapeutics, INC. | $135.72 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $106.64 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sunovion Pharmaceuticals INC. | $99.44 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.93 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $96.47 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabian Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.